Benchmark says 2021 results will be better than expected

© Daniel Lynch
Trond Williksen

Aquaculture biotechnology business Benchmark is set to outdo market expectations for its full year financial results, the company has said.

In a market announcement this morning, Benchmark said that it expected to report “a stronger than expected trading performance across its three business areas” for the year to 30 September 2021.

This includes continuing growth for the Animal Nutrition division, a strong end to the year for Benchmark Genetics and, for the Health division, the first revenues coming in from the company’s new sea lice treatment, Ectosan® Vet and CleanTreat®.

The full year results will be announced on 29 November.

The company said: “Whilst still subject to audit, the Group’s Adjusted EBITDA for FY21 is expected to be significantly ahead of the current market consensus which is £15.9m.”

Trond Williksen, CEO, commented: “We are pleased by the continuing momentum in the business, which reflects the benefits of our clear commercial focus, having streamlined the organisation, our continued disciplined approach to cost control and good demand for our products in our recovering markets.

“As a focused aquaculture biotechnology company with three strong business areas, we are well positioned to capture market opportunities and deliver profitable growth.”